Vision Sciences (CGNT) and SpectraScience (SCIE) Head to Head Survey

Share on StockTwits

Vision Sciences (NASDAQ:CGNT) and SpectraScience (OTCMKTS:SCIE) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Profitability

This table compares Vision Sciences and SpectraScience’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vision Sciences -1.57% -1.39% -1.21%
SpectraScience N/A N/A N/A

Institutional & Insider Ownership

14.5% of Vision Sciences shares are held by institutional investors. Comparatively, 0.0% of SpectraScience shares are held by institutional investors. 62.7% of Vision Sciences shares are held by insiders. Comparatively, 0.5% of SpectraScience shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Vision Sciences and SpectraScience’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vision Sciences $56.32 million 4.16 -$880,000.00 ($0.01) -385.00
SpectraScience N/A N/A -$4.46 million N/A N/A

Vision Sciences has higher revenue and earnings than SpectraScience.

Volatility & Risk

Vision Sciences has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Comparatively, SpectraScience has a beta of 3.14, suggesting that its share price is 214% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Vision Sciences and SpectraScience, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vision Sciences 0 2 0 0 2.00
SpectraScience 0 0 0 0 N/A

Vision Sciences currently has a consensus price target of $4.38, suggesting a potential upside of 13.64%. Given Vision Sciences’ higher probable upside, research analysts clearly believe Vision Sciences is more favorable than SpectraScience.

Summary

Vision Sciences beats SpectraScience on 5 of the 9 factors compared between the two stocks.

Vision Sciences Company Profile

Cogentix Medical, Inc., a medical device company, designs, develops, manufactures, and markets fiberoptic and video endoscopy products under the PrimeSight brand worldwide. The company offers endoscopes, such as cystoscopes, laryngoscopes, transnasal esophagoscopes, and bronchoscopes for medical use; and borescopes for industrial use, as well as digital processing units for medical use. It also provides EndoSheath Protective Barrier, a sterile, single-use microbial barrier for use with flexible endoscopes. In addition, the company offers Urgent PC System, a neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder; and Macroplastique, an injectable, urethral bulking agent for the treatment of adult female stress urinary incontinence. Further, it provides Macroplastique products for the treatment of vesicoureteral reflux; PTQ Implants to treat fecal incontinence; Urgent PC System for the treatment of fecal incontinence; and VOX Implants to enhance speech and swallowing function in patients with unilateral vocal cord paralysis. Additionally, the company distributes wound care products in the Netherlands and the United Kingdom. Cogentix Medical, Inc. sells its products through a direct sales force and a network of distributor organizations. The company was founded in 1987 and is headquartered in Minnetonka, Minnesota.

SpectraScience Company Profile

SpectraScience, Inc. develops and markets a technology platform to instantly determine whether a tissue is normal, pre-cancerous, or cancerous without the need for a physical biopsy in the United States, Europe, and internationally. It offers WavSTAT3 optical biopsy system to determine whether a colon tissue is normal, pre-cancerous, or cancerous without physically removing tissue from the body; and WavSTAT4 optical biopsy system, a colon diagnostic product that operates by using UV laser light to optically illuminate and analyze tissue, enabling the physician to make an instant diagnosis during endoscopy when screening for cancer. The company also sells mobile consoles and disposable forceps. In addition, it engages in developing an esophageal diagnosis application for the detection of pre-cancerous and cancerous tissues in various tissues of the body. The company was formerly known as GV Medical, Inc. and changed its name to SpectraScience, Inc. in October 1992. SpectraScience, Inc. was founded in 1983 and is based in San Diego, California.

Receive News & Ratings for Vision Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply